08 January 2020
Visiongain’s new report the Primary Cell Culture Market Report 2019-2029: Forecasts by Origin (Hematopoietic Cells, Skin Cells, Gastrointestinal Cells, Liver Cells, Lung Cells, Renal Cells, Muscle Cells, Other Cells), by Type (Human, Animal), by End User (Life Science Research Companies, Research Institutes), plus analysis of leading companies operating in the global primary cell culture market.
Fewer chances of mutations and modifications, reducing testing cost, growing production of regenerative medicines, rising research & development in biotechnology and increasing demand for stem cell therapy is expected to drive global primary cell culture market over the projected period. In 2019, global primary cell culture market revenue was valued at $779 million and is expected to reach $1.80 billion by 2029 at a CAGR of 8.7%. Other major factors driving the growth of primary cell culture market are growing prevalence of cancer and other chronic diseases all over the world. According to the National Cancer Institute, in 2018, more than 1.5 million new cases of cancer were diagnosed in the United States and more than 600k people died from cancer.
The drain of chronic diseases is rapidly increasing worldwide. According to the World Health Organization, in 2001, chronic diseases contributed approximately 60% of the 56.5 million total reported deaths in the world and approximately 46% of the global burden of disease. The proportion of the burden of chronic diseases is expected to increase to 57% by 2020. This, in turn, is expected to propel the primary cell culture industry over the coming years.
By region, North America dominated the global primary cell culture industry in 2019 and is expected to grow by virtue of technological advancement followed by well-developed healthcare infrastructure. Additionally, development and introduction of cell culture technologies coupled with increasing adoption of advanced therapies in Canada, the United States, and Mexico are expected to help market expansion over the coming years. Moreover, hectic lifestyle, increasing working hours, increasing working population, and consumer trends towards unhealthy foods has increased prevalence of chronic diseases in this region, which is expected to encourage primary cell culture industry over the projected period.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
. The growth of this market is majorly driven by increasing sales of temperature sensitive pharmaceutical products, longer life expectancy and rising geriatric population are some of the prominent factors.
16 September 2020
Visiongain forecasts a continuing growth in global market, submarket and product sales as human vaccines drive pharmaceutical business sales. New key players and technological progress will enter the industry, leading to an increase in the market size of the world market for human vaccines in general.
14 September 2020
The global ophthalmic ultrasound systems market is driven by factors such as the increasing prevalence of ocular disorders and diseases, adoption of novel ophthalmic technologies, rising focus on research & development, and growing health awareness amongst the population.
09 September 2020
The current COVID-19 pandemic is anticipated to have a minor impact on the overall outsourcing business outlook for global drug discovery. Also, significant growth during the COVID-19 pandemic is expected to be seen in the outsourcing of drugs and medicines needed to treat COVID-19 infections.